← All trials
NCT04583995
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Jan 14, 2022
- First posted
- Oct 12, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 15000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovavaxLead sponsor
- NovavaxStudy director
- University of LondonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.